August 24, 2020Open Access

Drug Resistance in Hematological Malignancies

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

Hematological malignancies define a highly heterogeneous set of blood-, bone marrow-, and organ-associated diseases with highly variable prognoses that constantly relapse upon treatment ....

Me gusta

Guardar

Ver artículo completo

Me gusta

Guardar

Ver artículo completo

Cite This Study

Auberger et al. (Mon,) studied this question.

synapsesocial.com/papers/6a321433ddc7ffcb4ccc13cf https://doi.org/https://doi.org/10.3390/ijms21176091

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Acadesine Circumvents Azacitidine Resistance in Myelodysplastic Syndrome and Acute Myeloid Leukemia2019 · 15 citations
2Setting Fire to ESA and EMA Resistance: New Targeted Treatment Options in Lower Risk Myelodysplastic Syndromes2019 · 25 citations
3Resistance Mechanisms to CAR T-Cell Therapy and Overcoming Strategy in B-Cell Hematologic Malignancies2019 · 59 citations
4Autophagy: New Insights into Mechanisms of Action and Resistance of Treatment in Acute Promyelocytic leukemia2019 · 53 citations
5Heterogeneous Pattern of Dependence on Anti-Apoptotic BCL-2 Family Proteins upon CHOP Treatment in Diffuse Large B-Cell Lymphoma2019 · 21 citations